Retinol binding protein 4 (RBP4)was a class of secreting protein,mainly synthesized by the liver,widely distribu-ted in the human body blood,urine and other body fluids.It plays an important role in assisting the physiological function of vitamin A[1].Recent research shows that RBP4 was a new kind of adipocytokine,participated in insulin resistance and occur-rence of type 2 diabetes,and had a closed relationship with diabetic nephropathy,nutritional disease.This article describes the function of RBP4,review the relationship between RBP4 and nutritional or other type of diseases,and new clinical detec-tion method with RBP4.

Objective:To analyse the biological function of anti-IL-6Rβ(gp130) monoclonal antibody and its regulatory effect on IL-6 signaling.Methods:Biological characteristics of anti-IL-6Rβ(gp130) mAb were assessed by Western blot analysis, capture ELISA and peptide ELISA .The phosphorylation of STAT 3 was tested by Western blot analysis in IL-6-stimulated U266/RA-FLS/RA-PBMC with or without anti-IL-6Rβ(gp130) mAb treatment.Results:3 strains of mouse anti-human gp130 mAb were with high affini-ty and different binding epitopes , the kaff of 10A1 was 2.62E-10.In U266, RA-PBMC and RA-SFMC, IL-6 signaling highly activated STAT3 which could be inhibited by anti-gp130 mAb.Conclusion: Anti-IL-6Rβ( gp130 ) mAb might have different binding epitopes and could affect IL-6 stimulated phosphorylation of STAT3, which provides a preliminary experiment for analyse the correlation of IL-6 signaling and RA .

In recent years, with the introduction of medical information technology from large medical institutions to communities and health management institutions and real-world data in the actual clinical diagnosis and treatment is increasingly abundant, the inherent needs of medical research methodologies are colliding with information technology, and resources are begining to transform to the application. Real-world data began to transform into clinical research evidence, providing objective conditions for the development of TCM real-world study. This paper analyzes and discusses the main characteristics of TCM real-world study, and provides reference for deepening the understanding and methodology of TCM real-world study.

Objective: To evaluate the clinical effects of combination of traditional Chinese and Western medicine in the treatment of primary epilepsy. Methods: The China Journal Full-text Database, science and Technology Journal Full-text Database, Wanfang database, PubMed database, EMbase were searched on the treatment of primary epilepsy literature combining traditional Chinese and Western medicine, and the system evaluation and meta-analysis were performed.Results: A total of 11 studies with 951 cases of primary epilepsy were included in the randomized controlled trial. The meta-analysis showed that the clinical effects of treatment of epilepsy group with combination of TCM and Western Medicine (RR=1.18, 95％ CI: 1.07-1.29, P ＜ 0.01), incidence frequency (WMD =-0.98, 95％ CI: 1.56-0.40), electrocardiogram improvement rate (RR=1.28, 95％ CI: 1.11-1.47, P ＜ 0.01) were significantly better than western medicine treatment (control group) . Conclusion: The effects of combined traditional Chinese and Western Medicine on primary epilepsy based on the method of latent town collaterals is superior to that of pure western medicine.

In real world clinical studies,standardized data acquisition method is a key step in the formation of reliable clinical evidence.This article described how to carry out clinical data collection and how to preprocess data in order to ensure the quality of data.The results showed that from the data sources,data collection contents,collection key points,data description and evaluation,this paper put forward the method of collecting the real world data of traditional Chinese medicine (TCM).It was concluded that the standardized methods of clinical data acquisition had laid a solid foundation for real world research.